BioCentury | May 14, 2012
Financial News

Retrophin completes venture financing

...N.Y. Business: Renal, Musculoskeletal, Pulmonary Date completed: 5/7/12 Type: Venture financing Raised: $4 million Investors: MSMB Capital...
BioCentury | Feb 20, 2012
Company News

SeraCare deal

...a process to explore and evaluate strategic alternatives, including a sale. In June, hedge fund MSMB Capital Management LLC...
BioCentury | Oct 24, 2011
Clinical News

Lymphoseek tilmanocept regulatory update

...Neoprobe filed a formal response to a June 2 Citizen's Petition submitted by hedge fund MSMB Capital...
BioCentury | Oct 17, 2011
Finance

Accept / reject / reset

...to AMAG shareholders, ISS supported neither the merger nor an an unsolicited offer made by MSMB Capital Management LLC...
BioCentury | Oct 17, 2011
Company News

Allos, AMAG Pharmaceuticals deal

...was first announced, it valued Allos at $258 million (see BioCentury, July 25). Separately, investor MSMB Capital Management LLC...
BioCentury | Sep 19, 2011
Company News

Allos deal

...than $500 million (see BioCentury, July 25). In August, AMAG rejected an offer from shareholder MSMB Capital...
BioCentury | Sep 15, 2011
Company News

Allos rejects unsolicited offer, maintains AMAG merger plans

...$1.64 (see BioCentury Extra, July 20) . In August, AMAG rejected an offer from shareholder MSMB Capital...
BioCentury | Aug 15, 2011
Finance

Rebalancing act

...potential deal. Last week, it rejected an $18 per share cash bid ($380.9 million) from MSMB Capital...
BioCentury | Aug 15, 2011
Finance

Highlights of weekly biotech stock moves

...$0.85 to $14.97 last week after its board unanimously rejected an unsolicited offer from shareholder MSMB Capital...
BioCentury | Aug 15, 2011
Clinical News

Lymphoseek tilmanocept regulatory update

...Neoprobe filed a formal response to a June 2 Citizen's Petition submitted by hedge fund MSMB Capital...
Items per page:
1 - 10 of 20
BioCentury | May 14, 2012
Financial News

Retrophin completes venture financing

...N.Y. Business: Renal, Musculoskeletal, Pulmonary Date completed: 5/7/12 Type: Venture financing Raised: $4 million Investors: MSMB Capital...
BioCentury | Feb 20, 2012
Company News

SeraCare deal

...a process to explore and evaluate strategic alternatives, including a sale. In June, hedge fund MSMB Capital Management LLC...
BioCentury | Oct 24, 2011
Clinical News

Lymphoseek tilmanocept regulatory update

...Neoprobe filed a formal response to a June 2 Citizen's Petition submitted by hedge fund MSMB Capital...
BioCentury | Oct 17, 2011
Finance

Accept / reject / reset

...to AMAG shareholders, ISS supported neither the merger nor an an unsolicited offer made by MSMB Capital Management LLC...
BioCentury | Oct 17, 2011
Company News

Allos, AMAG Pharmaceuticals deal

...was first announced, it valued Allos at $258 million (see BioCentury, July 25). Separately, investor MSMB Capital Management LLC...
BioCentury | Sep 19, 2011
Company News

Allos deal

...than $500 million (see BioCentury, July 25). In August, AMAG rejected an offer from shareholder MSMB Capital...
BioCentury | Sep 15, 2011
Company News

Allos rejects unsolicited offer, maintains AMAG merger plans

...$1.64 (see BioCentury Extra, July 20) . In August, AMAG rejected an offer from shareholder MSMB Capital...
BioCentury | Aug 15, 2011
Finance

Rebalancing act

...potential deal. Last week, it rejected an $18 per share cash bid ($380.9 million) from MSMB Capital...
BioCentury | Aug 15, 2011
Finance

Highlights of weekly biotech stock moves

...$0.85 to $14.97 last week after its board unanimously rejected an unsolicited offer from shareholder MSMB Capital...
BioCentury | Aug 15, 2011
Clinical News

Lymphoseek tilmanocept regulatory update

...Neoprobe filed a formal response to a June 2 Citizen's Petition submitted by hedge fund MSMB Capital...
Items per page:
1 - 10 of 20